1stOncology™: Cancer Intelligence Service – Page 111 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

On May 27, 2026 Bristol Myers Squibb (NYSE: BMY) reported that the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The company will take part in a fireside chat beginning at 2:00 p.m. ET.

Investors and the general public are invited to listen to the session by visiting View Source An archived edition of the session will be available following its conclusion.

(Press release, Bristol-Myers Squibb, MAY 27, 2026, View Source [SID1234666093])

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

On May 27, 2026 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, reported its unaudited financial results for the quarter ended March 31, 2026, and provided a corporate update.

"Since our last quarterly update, we achieved a significant milestone for our company and for the GLIX1 development program with the dosing of the first patient in our Phase 1/2a clinical trial of GLIX1 in glioblastoma," stated Philip Serlin, Chief Executive Officer of BioLineRx. "We are also very encouraged by compelling new pre-clinical data showing that GLIX1 demonstrated robust dose-dependent tumor-growth inhibition and survival benefit in orthotopic cell-derived xenograft (CDX) GBM models. Furthermore, in a newly completed subcutaneous TMZ-resistant patient-derived xenograft (PDX) GBM model, GLIX1 demonstrated a robust anti-tumor effect while no effect was observed with TMZ, highlighting the potential to address the very high unmet need in GBM."

"In the coming days, we look forward to engaging with the broader oncology community at this year’s ASCO (Free ASCO Whitepaper) meeting with two abstracts featuring GLIX1. The abstracts highlight its novel mechanism of action and provide strong rationale for the development of GLIX1 in GBM as well as in other cancers. They also highlight that in safety studies in animals GLIX1 was safe up to the highest feasible doses tested, supporting the combination with other anti-cancer agents. Furthermore, the abstracts highlight the compelling mechanistic rationale for combining GLIX1 with PARP inhibitors supported by synergistic effect in cell lines across diverse cancers including from tumor types typically less responsive to PARP inhibition."

Financial Updates

With $17.4 million on its balance sheet as of March 31, 2026, BioLineRx is maintaining its cash runway guidance into the first half of 2027.
Development Updates
GLIX1

Phase 1/2a clinical trial of GLIX1 in glioblastoma and other cancers initiated in March 2026.
The first patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center.
Two additional leading cancer centers are participating in the study: Northwestern University, led by Dr. Roger Stupp and Dr. Ditte Primdahl; and Moffit Cancer Center, led by Dr. Patrick Grogan. Additional sites may be added to the study at a later date.
The Phase 1 part of the trial is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy.
The Phase 2a expansion part of the trial is planned to include additional indications, including newly diagnosed GBM, as well as select cancers, with GLIX1 as monotherapy or in combination with standard of care (including in combination with PARP inhibitors). These cohorts are expected to identify preliminary efficacy, PD assessments and dose optimization data, serving as the basis for a rapid and effective advanced clinical development plan.
Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model
Announced two abstracts on GLIX1 that were selected for publication during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which is scheduled for May 29-June 2, in Chicago, IL.
Pre-clinical activities in support of clinical development for GLIX1 in additional cancer indications, including in combination with PARP inhibitors, are ongoing.
Motixafortide
Pancreatic Ductal Adenocarcinoma (mPDAC)

Enrollment is continuing in the CheMo4METPANC Phase 2b clinical trial, which is being led by Columbia University, and supported by both Regeneron and BioLineRx. The trial is evaluating motixafortide in combination with the PD-1 inhibitor cemiplimab and standard chemotherapy (gemcitabine and nab-paclitaxel).
A prespecified interim/futility analysis is planned when 40% of progression-free survival (PFS) events are observed, which the Company continues to anticipate will occur in 2026.
APHEXDA Performance Update

APHEXDA sales for the first quarter of 2026 were $2.7 million, which provided royalty revenues to the company of $0.5 million.
Financial Results for the Quarter ended March 31, 2026

Revenues for the three months ended March 31, 2026 were $0.5 million, an increase of $0.2 million, compared to revenues of $0.3 million for the three months ended March 31, 2025. The increase in revenues from 2025 to 2026 reflects an increase in royalties paid by Ayrmid from the commercialization of APHEXDA.
Cost of revenues for the three months ended March 31, 2026 was $0.1 million, compared to immaterial cost of revenues for the three months ended March 31, 2025. The cost of revenues reflects sub-license fees on royalties paid by Ayrmid from the commercialization of APHEXDA.
Research and development expenses for the three months ended March 31, 2026 were $2.5 million, an increase of $0.9 million, or 55.8%, compared to $1.6 million for the three months ended March 31, 2025. The increase resulted primarily from expenses related to the new GLIX1 project.
General and administrative expenses for the three months ended March 31, 2026 were $0.9 million, a decrease of $0.1 million, or 13.3%, compared to $1.0 million for the three months ended March 31, 2025. The decrease resulted primarily from a decrease in legal expenses, as well as a decrease in a number of other general and administrative expenses.
Net non-operating income amounted to $0.5 million for the three months ended March 31, 2026, compared to net non-operating income of $7.6 million for the three months ended March 31, 2025. Non-operating income for the periods primarily relates to non-cash fair-value adjustments of warrant liabilities, as a result of changes in the Company’s share price, offset by warrant offering expenses.
Net financial expenses for the three months ended March 31, 2026 were immaterial compared to net financial expenses of $0.1 million for the three months ended March 31, 2025. Net financial expenses for the periods primarily relate to interest paid on loans, partially offset by investment income earned on bank deposits.
Net loss for the quarter ended March 31, 2026 was $2.6 million, compared to net income of $5.1 million for the quarter ended March 31, 2025.
As of March 31, 2026, the Company had cash, cash equivalents, and short-term bank deposits of $17.4 million.
Conference Call and Webcast Information
To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 28, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

(Press release, BioLineRx, MAY 27, 2026, View Source [SID1234666089])

Sapreme Development B.V. to become Sapreme Therapeutics B.V.

On May 27, 2026 Sapreme Development reported as company continues to evolve, it is excited to announce that effective June 1st, 2026, Sapreme Development B.V. will become Sapreme Therapeutics B.V.

Over the past years, our focus has progressed from platform technology toward the development of a growing portfolio of therapeutic programs.

Our new name reflects that evolution and our future as a therapeutics-focused biotech company.

This is a name change only, and we look forward to continuing this journey together with our partners, collaborators, and broader network.

(Press release, Sapreme Technologies, MAY 27, 2026, View Source [SID1234666088])

Genomic Testing Cooperative to Exhibit and Present Research at 2026 ASCO Annual Meeting

On May 27, 2026 Genomic Testing Cooperative, a molecular diagnostics company advancing comprehensive cancer profiling through DNA and RNA analysis, reported it will exhibit and present research at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. ASCO (Free ASCO Whitepaper) 2026 will bring together the global oncology community to explore high-impact cancer research, clinical advances, and new technologies shaping the future of cancer care. More than 3,400 abstracts are expected to be presented at this year’s meeting.

WHAT:
GTC will be available throughout ASCO (Free ASCO Whitepaper) 2026 to connect with media, oncology leaders, industry analysts, financial analysts, pharmaceutical companies, cancer centers, laboratories and potential strategic partners interested in the company’s comprehensive testing platform, cooperative business model and approach to precision cancer diagnostics.

WHEN:
May 29 to June 2, 2026

WHERE:
McCormick Place, Chicago – Booth #17146

GTC PRESENTATIONS AND AFFILIATED POSTERS:

Details for each presentation are available at genomictestingcooperative.com/asco2026/, and the posters will be posted here after ASCO (Free ASCO Whitepaper).

Session: Hematologic Malignancies | Lymphoma and Chronic Lymphocytic Leukemia

Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile.

Date: Jun 1, 2026 – 9 AM – 12PM CDT

Abstract: 7075 Poster Board 573

Session: Breast Cancer | Metastatic

Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.

Date: Jun 1, 2026 – 1:30-4:30 PM CDT

Abstract: 1035 Poster Board 149

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

Distinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without FLT3 mutation.

Date: Jun 1, 2026 – 9 AM – 12PM CDT

Abstract: 6538 Poster board 331

Session: Developmental Therapeutics | Molecularly Targeted Agents and Tumor Biology

Comprehensive profiling and clinical utility of CSF-derived cell-free DNA/RNA for evaluation of solid and hematologic malignancies affecting the central nervous system.

Date: May 30, 2026

Abstract: 3066 Poster Board 203

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

TP53 mutation adoption of stromal-adhesion/neuronal-like programs as a driver of stress adaptation and acute myelogenous leukemia cell survival.

Date: Jun 1, 2026

Abstract: 6545 Poster Board: 338

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

A two-axis machine learning framework for cell-of-origin inference in AML: A proof-of-concept study.

Date: Jun 1, 2026

Abstract: 6540 Poster Board: 333

MEDIA AND ANALYST OPPORTUNITIES
Members of the media, industry analysts and financial analysts may schedule meetings with GTC leadership to discuss:

New research being presented at ASCO (Free ASCO Whitepaper) 2026

The role of comprehensive DNA and RNA testing in precision oncology
Liquid biopsy applications, including CSF-based testing for cancers affecting the central nervous system
GTC’s approach to hematologic malignancies, solid tumors and metastatic disease
The company’s cooperative model and opportunities for laboratories, oncology practices and strategic partners
GTC’s growth strategy, including opportunities to expand access to comprehensive molecular testing
WHY GTC MATTERS:
Cancer is complex, and treatment decisions increasingly depend on complete molecular information. GTC’s platform analyzes both DNA and RNA to help identify clinically meaningful biomarkers that more limited testing approaches may miss. GTC approach in RNA sequencing and utilization with artificial intelligence has lead to multiple new tests and discovery of unique biomarkers. For oncologists, pathologists, cancer centers, laboratories and research partners attending ASCO (Free ASCO Whitepaper), GTC offers a differentiated model designed to support comprehensive cancer profiling, clinical interpretation and broader access to precision diagnostics.

WHO:
GTC leaders available for interviews and briefings include:

Maher Albitar, MD, Founder, CEO and Chief Medical Officer
Ahmad Charifa, MD
Adam Zrinsky Albitar, MD
Jennifer Varca, President
Jeff Owen, VP, Marketing and International Sales
Colleen Zirpoli, VP, Sales
To schedule a meeting with GTC at ASCO (Free ASCO Whitepaper) 2026, contact Cara Stewart at [email protected] or +1 949-290-5563; details are available at genomictestingcooperative.com/asco2026.

(Press release, Genomic Testing Cooperative, MAY 27, 2026, View Source [SID1234666087])

Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies

On May 26, 2026 Biomunex Pharmaceuticals, a biopharmaceutical company specialized in the discovery and development of innovative immunotherapies based on bispecific and multi-specific antibodies, reported two new strategic collaborations with AI-driven companies, Gordion Bioscience and Tangramed Biotech. These partnerships are fully aligned with Biomunex’s ongoing strategy to further integrate relevant AI into all its scientific processes to further accelerate the discovery and development processes of novel immunotherapeutic approaches in oncology.

Under the first research collaboration, Biomunex will work with Gordion Bioscience, a US-based AI-driven oncology company, specializing in patient-derived biological network analysis and computational target discovery, to identify novel bispecific target combinations in oncology. The objective is to reinforce Biomunex’s innovative pipeline with original pairs of targets and new differentiated therapeutic candidates for cancer treatment.

In a complementary approach, Biomunex has entered into a second research collaboration with Tangramed Biotech, a France-based AI-enabled biotech company, developing multimodal target-combination discovery approaches powered by biomedical data analytics. The objective is to uncover and prioritize actionable therapeutic opportunities, to identify novel target combinations that could leverage Biomunex’s proprietary BiXAb platforms. This collaboration is expected to leverage generative AI, for the identification of novel therapeutic candidates in solid tumors and hematological malignancies.

These two collaborations reflect Biomunex’s commitment to combining the scientific strength of its proprietary platform technologies with the capabilities offered by AI in several R&D axes, particularly to optimize target selection, shorten discovery timelines, and increase the probability of translational success.

"Biomunex has developed with BiXAb one of the most versatile and efficient technologies for the generation of bispecific antibodies. Gordion’s framework uncovers co-essential target pairs that conventional expression-based approaches often fail to detect. Gordion will systematically explore a broad landscape of target combinations, surfacing clinically differentiated pairs for breakthrough bispecific antibodies," adds Dr. Pawel Zawadzki, CEO of Gordion Bioscience.

"Translating the power of generative AI and biomedical data analytics into concrete and clinical impact is exemplified in this collaboration with Biomunex. By combining our AI-driven platform with Biomunex’s BiXAb technologies, we believe that Tangramed will help Biomunex further accelerate the identification of high-value target combinations to create next-generation immunotherapies in oncology," comments Dr. Jinchao Yu, CSO of Tangramed Biotech.

"Artificial intelligence has become a major driver of innovation in drug discovery. By combining our expertise in bispecific and multi-specific antibodies and our BiXAb platforms with the technologies developed by AI-driven companies, such as Tangramed Biotech and Gordion Bioscience, we are strengthening our ability to rapidly identify new therapeutic opportunities in oncology," comments Dr. Simon Plyte, CSO of Biomunex.

Dr. Pierre-Emmanuel Gerard, Founding President and CEO of Biomunex adds: "Biomunex has established for a long time a very cost- and time-effective process to bring disruptive innovation thanks to our BiXAb technologies, as well as our know-how in molecular modeling or in-silico design. These deals represent a step forward in our AI strategy, to accelerate even more our process to generate and develop new breakthrough clinical candidates".

One of the current Biomunex’s goals is indeed to further integrate AI in all parts of the company, not only for R&D programs, but also general corporate resources, such as finance, accounting, human resources & recruitment and legal topics.

(Press release, BIOMUNEX Pharmaceuticals, MAY 26, 2026, View Source [SID1234666085])